Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma

BACKGROUND: The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the response to immune checkpoint therapy and improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Que, Yi, Zhang, Xiao-Long, Liu, Ze-Xian, Zhao, Jing-Jing, Pan, Qiu-Zhong, Wen, Xi-Zhi, Xiao, Wei, Xu, Bu-Shu, Hong, Dong-Chun, Guo, Tian-Hui, Shen, Lu-Jun, Fan, Wei-Jun, Chen, Huo-Ying, Weng, De-Sheng, Xu, Hai-Rong, Zhou, Peng-Hui, Zhang, Yi-Zhuo, Niu, Xiao-Hui, Zhang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919591/
https://www.ncbi.nlm.nih.gov/pubmed/33637599
http://dx.doi.org/10.1136/jitc-2020-001696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919591/
https://www.ncbi.nlm.nih.gov/pubmed/33637599
http://dx.doi.org/10.1136/jitc-2020-001696

Ejemplares similares